HIF1A and chronic kidney disease: As an oxidative stress sensor, HIF-1α is involved in many biological processes in response to systemic oxygen levels.40–45 Rox is a first PHD inhibitor to stimulate HIF-1α expression and activity and was approved by FDA in 2018 for the treatment of anaemia in patients with chronic kidney disease and in patients with myelodysplastic syndromes.